ArticleInflammopharmacology2025
Phytofabricated Farsetia aegyptia-derived silver nanoparticles mediate antibacterial and wound-healing activities in diabetic foot infection rat model.
Article in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Biologically Mediated Nanoparticle Synthesis as a Potential Green Strategy: Principles, Methods, and Pharmaceutical Applications.Pharmaceutics · 2026Review
- BiogenicFrontiers in medicine · 2026Article
- Metabolism, senescence, and natural products: new perspectives on wound healing in diabetes.Frontiers in nutrition · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Diabetic foot infection (DFI) leads to delayed wound healing in diabetic patients and is a significant cause of foot amputation. Others and we reported the efficient use of green-synthesized nanoparticles in promoting skin wound healing. In this research, we targeted to green-synthesized silver nanoparticles (AgNPs) using aqueous extract of the wild-plant Farsetia aegyptia (FA-AgNPs) and to investigate their antibacterial effect and wound-healing capacity in DFI rat model. Gas chromatography-mass spectrometry revealed a high concentration of biologically active phytochemicals with antibacterial and antidiabetic properties. Several characterization techniques were employed to confirm the biosynthesis of FA-AgNPs. Interestingly, FA-AgNPs showed significant antibacterial action against the multidrug-resistant DFI-derived Staphylococcus aureus. Mechanistic studies revealed that FA-AgNPs exerted antibacterial action via increasing ROS accumulation, membrane leakage, permeability, and distraction of surface structure in the DFI S. aureus. Several anti-biofilm tests and microscopic studies confirmed that FA-AgNPs effectively suppress biofilm formation. The wound-healing activity of FA-AgNPs was explored in DFI rat model infected with S. aureus isolated from DFI patients. Histological and immunohistochemical analysis of skin wound revealed enhanced wound-healing features in the FA-AgNPs-treated DFI group, including increased cellular proliferation, reduced inflammation, increased collagen deposition, and angiogenesis. In addition, FA-AgNPs significantly inhibited bacterial burden in foot ulcers. The mode of FA-AgNPs action to enhance wound healing in DFI model was found to be mediated by activating transforming growth factor β1(TGF-β1)/Smad pathway and increasing the expression of angiogenesis markers vascular endothelial growth factor-A (VEGF-A) and platelet-derived growth factor β (PDGF-β). In addition, FA-AgNPs displayed anti-inflammatory effect by inhibiting the Toll-like receptor 4/Nuclear factor kappa B (TLR-4/NF-κB) signaling as determined by western blot examination. In conclusion, FA-AgNPs could provide a novel green therapeutic strategy for promoting wound healing in DFI.
Indexed as
Identifiers
40461756What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.